Labopharm is notified of Actavis' filing for a generic Oleptro

11/14/2010 | Reuters

Actavis has notified Labopharm of its FDA filing for a generic version of Oleptro, the latter's once-daily treatment for depression. Labopharm, which is reviewing the formal notice, has market exclusivity for the drug through Feb. 2, 2013.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT